The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• LY3437943 is a novel single peptide derived from a GIP peptide backbone with triple agonist activity on GIP, GLP-1, and glucagon receptors.
• Preclinical animal models found LY3437943 acutely enhances glucose-dependent insulin secretion in rats, and decreased fasting glucose and insulin in obese mice.
• There was also reduced food intake and increased energy expenditure, resulting in body weight loss superior to liraglutide and tirzepatide.
• LY3437943 also decreased liver triglycerides and improved biomarkers of liver health in obese mice.